The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population
NCT ID: NCT05159544
Last Updated: 2024-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60000 participants
OBSERVATIONAL
2021-07-06
2024-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Female Asian Nonsmoker Screening Study
NCT05164757
Identify Prognostic Biomarkers of Lung Cancer
NCT05010330
INSPIRE: a Multi-Cancer Early Detection Study
NCT06440018
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
NCT05874648
Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients
NCT04980352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multi-omics model developing and training arm
Blood samples and individual health information from 50,000 participants in community, who got 3-year follow-up are selected.
No interventions assigned to this group
Multi-omics model validating arm
10,000 participants in routine annual physicals from hospitals will be selected, and they will be followed up for 2 years.
No interventions assigned to this group
Multi-omics model evaluating arm
Participants in Taizhou cohort will be selected.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. "Population Health tracking Survey - simplified version of the questionnaire" must be filled according to the research program and an annual physical examination can be received as follow-up ;
3. Timely feed back the information related to tumor diagnosis in other hospitals to the investigator during the program;
4. Have no birth plan for the last 3 years;
5. Fully understand the study and voluntarily sign the informed consent.
Exclusion Criteria
2. Received blood transfusion, transplantation and other major operations within 3 months;
3. Participated in other interventional clinical researchs within 3 months;
4. Pregnant or lactating women;
5. Patients with autoimmune diseases, genetic diseases, mental diseases/disabilities and other diseases considered unsuitable for the study by the investigator;
6. Due to poor compliance, the researcher judged that the study could not be completed.
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Singlera Genomics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xingdong Chen, Ph.D
Role: STUDY_DIRECTOR
Fudan University Taizhou Institute of Health Sciences, Taizhou, China
Rui Liu, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Singlera Genomics Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, Anhui, China
Beijing Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Union Hospital affiliated to Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Fudan University Taizhou Institute of Health Sciences, Taizhou, China
Taihou, Jiangsu, China
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wen Zou, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Chen X, Gole J, Gore A, He Q, Lu M, Min J, Yuan Z, Yang X, Jiang Y, Zhang T, Suo C, Li X, Cheng L, Zhang Z, Niu H, Li Z, Xie Z, Shi H, Zhang X, Fan M, Wang X, Yang Y, Dang J, McConnell C, Zhang J, Wang J, Yu S, Ye W, Gao Y, Zhang K, Liu R, Jin L. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020 Jul 21;11(1):3475. doi: 10.1038/s41467-020-17316-z.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FuSion
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.